DATATRAK Exhibiting at the DIA's 3rd Annual Clinical Forum in Nice, France
October 13 2009 - 7:37PM
PR Newswire (US)
CLEVELAND, Oct. 13 /PRNewswire-FirstCall/ -- DATATRAK
International, Inc. (OTCQX: DATA), a technology and services
company focused on global eClinical solutions for the clinical
trials industry, today announced its attendance at the 3rd Annual
Clinical Forum in Nice, France. DATATRAK will be exhibiting in
Booth 19 at the Nice Acropolis on October 19-21, 2009. Visit the
booth to see how DATATRAK ONE(TM) technology and services provide
the comprehensive and cohesive solution you need for delivering all
your clinical trials in one system with one database. We are
offering demonstrations that give you a firsthand look at our fast
reporting, unrivaled stability and enhanced usability. If you would
like to schedule a personal demonstration during the show, please
send an email to . About DIA 3rd Annual Clinical Forum. Join new
and experienced colleagues in the field of clinical and safety data
management, statistics, medical information, medical writing,
pharmacovigilance, information technology and validation in
attending a wide range of educational forums, discuss experiences
and uncover solutions. For more information on the DIA's 3rd Annual
Clinical Forum, see http://www.diahome.org/ About DATATRAK
International, Inc. DATATRAK International, Inc. is a worldwide
technology and services company focused on the provision of
multi-component eClinical solutions and related services for the
clinical trials industry. We operate under the concept of DATATRAK
ONE(TM), which encompasses our unique, single platform technology.
The singular architecture of our DATATRAK eClinical(TM) product
suite has been embraced by clients around the globe for its ability
to effectively manage clinical trials through a unified
multi-component, comprehensive solution. The Company delivers a
complete portfolio of software products that were created in order
to accelerate clinical research data from investigative sites to
clinical trial sponsors and ultimately the FDA, faster and more
efficiently than manual methods or loosely integrated technologies.
DATATRAK's eClinical(TM) software suite can be deployed worldwide
through an ASP offering or in a licensed Enterprise Transfer model
that fully empowers its clients. The DATATRAK software suite and
its earlier versions have successfully supported hundreds of
international clinical trials involving thousands of clinical
research sites and encompassing tens of thousands of patients in 59
countries. DATATRAK International, Inc.'s product suite has been
utilized in some aspect of the clinical development of 16 drugs and
one medical device that have received regulatory approval from
either the United States Food and Drug Administration or
counterpart European bodies. DATATRAK International, Inc. has
offices located in Cleveland, Ohio, and Bryan, Texas. Visit the
DATATRAK International, Inc. web site at http://www.datatrak.net/.
Except for the historical information contained in this press
release, the statements made in this release are forward-looking
statements. These forward-looking statements are made based on
management's expectations, assumptions, estimates and current
beliefs concerning the operations, future results and prospects of
the Company and are subject to uncertainties and factors (including
those specified below) which are difficult to predict and, in many
instances, are beyond the control of the Company. Factors that may
cause actual results to differ materially from those in the
forward-looking statements include the limited operating history on
which the Company's performance can be evaluated; the ability of
the Company to continue to enhance its software products to meet
customer and market needs; fluctuations in the Company's quarterly
results; the viability of the Company's business strategy and its
early stage of development; the timing of clinical trial sponsor
decisions to conduct new clinical trials or cancel or delay ongoing
trials; the Company's dependence on major customers; government
regulation associated with clinical trials and the approval of new
drugs; the ability of the Company to compete in the emerging EDC
market; losses that potentially could be incurred from breaches of
contracts or loss of customer data; the inability to protect
intellectual property rights or the infringement upon other's
intellectual property rights; the costs associated with maintaining
and/or developing two product suites; and general economic
conditions such as the rate of employment, inflation, interest
rates and the condition of capital markets. This list of factors is
not all-inclusive. In addition, the Company's success depends on
the outcome of various strategic initiatives it has undertaken, all
of which are based on assumptions made by the Company concerning
trends in the clinical research market and the health care
industry. The Company undertakes no obligation to update publicly
or revise any forward-looking statement whether as a result of new
information, future events or otherwise. DATASOURCE: DATATRAK
International, Inc. CONTACT: Raymond J. Merk, Chief Financial
Officer and Chief Operating Officer, DATATRAK International, Inc.,
+1-440-443-0082 x181 Web Site: http://www.datatrak.net/
Copyright